APACC 2017

Program implementer perspective- Fujie Zhang, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Community Perspective- Martin Choo, MMedSc

Slideset

HIV

Viral Hepatitis and Liver Disease

Key note lecture: HIV/AIDS in the Asia Pacific: Where is the Epidemic Heading?- Chris Beyrer

Slideset

HIV

Viral Hepatitis and Liver Disease

ART: are two drugs enough?- Mark Boyd, BA, BM, BS, DCTH&H, MHID, MD, FRACP

Slideset

HIV

Viral Hepatitis and Liver Disease

The SWORD study- Chien-Ching Hung, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in virologically suppressed asian adults with renal impairment- Dr. B. Chin

Slideset

HIV

Viral Hepatitis and Liver Disease

Cost effectiveness of a screening program for Cryptococcal antigenemia among ARV naive HIV inf. patients with CD4< 100 cell/cumm in a referral HIV care center at MCross Anonymous Clinic in Bangkok, Thailand: A five-year observational cohort- Dr. S. Rama

Slideset

HIV

Viral Hepatitis and Liver Disease

Identifying TB co-infection - new approaches- Charoen Chuchottaworn

Slideset

HIV

Viral Hepatitis and Liver Disease

Acute Shigellosis among HIV-infected people in 2015: An outbreak investigation- Dr. Y.T. Shen

Slideset

HIV

Viral Hepatitis and Liver Disease

HIV care in Yangon, Myanmar; successes, challenges and implications for policy- Dr. J. Hanson

Slideset

HIV

Viral Hepatitis and Liver Disease

The clinical utility of the urine based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: a prospective, hospital-based study-Dr. J. Hanson

Slideset

HIV

Viral Hepatitis and Liver Disease

HIV prevalence in men who have sex with men in Shinjuku 2-chome gay town, Tokyo: Result from the HIV testing program using the home collection kit- Dr. M. Takano

Slideset

HIV

Viral Hepatitis and Liver Disease

HIV testing as the bridge between awareness and acceptance of PrEP among MSM- Dr. T.H. Kwan

Slideset

HIV

Viral Hepatitis and Liver Disease

Mental health and neurocognitive issues related to adolescents who have grown up with HIV- Warren Y.K. NG

Slideset

HIV

Viral Hepatitis and Liver Disease

The emergence of transmitted protease inhibitor resistance mutations in adults starting antiretroviral therapy in northern Vietnam- Dr. T. Le

Slideset

HIV

Viral Hepatitis and Liver Disease

Highly automated deep sequencing-based HIV-1 drug resistance monitoring system- Dr. E. Rakhmanaliev

Slideset

HIV

Viral Hepatitis and Liver Disease

Drug interactions between anti-HCV Antivirals Ledipasvir/Sofosbuvir and integrase strand transfer inhibitor-based regimens- Dr. D. Mccoll

Slideset

HIV

Viral Hepatitis and Liver Disease

HIV and adolescents: How do we help them to prepare for adult lifeation?- Rangsima Lolekha

Slideset

HIV

Viral Hepatitis and Liver Disease

Transition into adult care: Factors associated with level of preparedness among adolescents living with HIV in Cambodia- Dr. S. Yi

Slideset

HIV

Viral Hepatitis and Liver Disease

Factors associated with HIV infection among transgender women in Cambodia: Results from a national integrated biological and behavioral survey- Dr. S. Yi

Slideset

HIV

Viral Hepatitis and Liver Disease

Renal disease and HIV- Sanjay Pujari

Slideset

HIV

Viral Hepatitis and Liver Disease

Cardiovascular disease and HIV- Somnuek Sungkanuparph

Slideset

HIV

Viral Hepatitis and Liver Disease

Assessment of atherosclerotic cardiovascular disease (ASCVD) risks between HIV-infected patients receiving first-line and second-line antiretroviral therapy- Dr. J. Tiarukkitsagul

Slideset

HIV

Viral Hepatitis and Liver Disease

Higher burden of chronic comorbidities among aged hospitalized HIV patients compared to non-HIV infected patients in Japan- Dr. D. Ruzicka

Slideset

HIV

Viral Hepatitis and Liver Disease

Prevalence of sarcopenia and associated risk factors among HIV-infected individuals receiving suppressive antiretroviral therapy- Dr. R. Rajasuriar

Slideset

HIV

Viral Hepatitis and Liver Disease

Recruiting people into HIV Services: eBooking- Panus Na Nakorn

Slideset

HIV

Viral Hepatitis and Liver Disease

Online platforms to spur HIV testing- Joseph Tucker, MD, PhD, AM

Slideset

HIV

Viral Hepatitis and Liver Disease

e-Cascade for real-time monitoring of HIV program- Matthew Avery

Slideset

HIV

Viral Hepatitis and Liver Disease

Consideration regarding the service model on pre-exposure prophylaxis for men who have sex with men in the community- Dr. T.H. Kwan

Slideset

HIV

Viral Hepatitis and Liver Disease

Pre-exposure prophylaxis uptake among men who have sex with men at a clinic in Bangkok, Thailand, 2016- Dr. W. Wimonsate

Slideset

HIV

Viral Hepatitis and Liver Disease

Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia- Dr. R. Sopha

Slideset

HIV

Viral Hepatitis and Liver Disease

Population-based PrEP implementation in New South Wales, Australia- Andrew Grulich

Slideset

HIV

Viral Hepatitis and Liver Disease

Round Table Discussion: True demand from the communities- Midnigh Poonkasetwattana

Slideset

HIV

Viral Hepatitis and Liver Disease

Round Table Discussion: Genuine supply from the providers- Rossana Ditangco

Slideset

HIV

Viral Hepatitis and Liver Disease

PrEP research and implementation gaps- Michael Cassell

Slideset

HIV

Viral Hepatitis and Liver Disease

Access to treatment/care on the global level- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Access to treatment/care on the country level- Giten Khwairakpam

Slideset

HIV

Viral Hepatitis and Liver Disease

Barriers to access - Community perspective- Martin Choo, MMedSc

Slideset

HIV

Viral Hepatitis and Liver Disease

New HIV drugs / regimens- Daniel Kuritzkes, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

New hepatitis drugs- Jürgen Rockstroh, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Innovative ways to stimulate the demand of HIV and HCV testing- Philip Cunningham

Slideset

HIV

Viral Hepatitis and Liver Disease

Effectively Communicating Your Research Objectives in Grant Applications - S. Lewin, AO, FRACP, PhD, FAHMS

Slideset

HIV

Viral Hepatitis and Liver Disease

APACC 2017

Program implementer perspective- Fujie Zhang, MD, PhD

Community Perspective- Martin Choo, MMedSc

Key note lecture: HIV/AIDS in the Asia Pacific: Where is the Epidemic Heading?- Chris Beyrer

ART: are two drugs enough?- Mark Boyd, BA, BM, BS, DCTH&H, MHID, MD, FRACP

The SWORD study- Chien-Ching Hung, MD, PhD

Efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in virologically suppressed asian adults with renal impairment- Dr. B. Chin

Cost effectiveness of a screening program for Cryptococcal antigenemia among ARV naive HIV inf. patients with CD4< 100 cell/cumm in a referral HIV care center at MCross Anonymous Clinic in Bangkok, Thailand: A five-year observational cohort- Dr. S. Rama

Identifying TB co-infection - new approaches- Charoen Chuchottaworn

Acute Shigellosis among HIV-infected people in 2015: An outbreak investigation- Dr. Y.T. Shen

HIV care in Yangon, Myanmar; successes, challenges and implications for policy- Dr. J. Hanson

The clinical utility of the urine based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: a prospective, hospital-based study-Dr. J. Hanson

HIV prevalence in men who have sex with men in Shinjuku 2-chome gay town, Tokyo: Result from the HIV testing program using the home collection kit- Dr. M. Takano

HIV testing as the bridge between awareness and acceptance of PrEP among MSM- Dr. T.H. Kwan

Mental health and neurocognitive issues related to adolescents who have grown up with HIV- Warren Y.K. NG

Aging among adults in the context of HIV- Reena Rajasuriar, MPharm, PhD

Neurocognitive issues among aging adults- Edwina Wright

Does resistance still matter?- Daniel Kuritzkes, MD

Clinical Case presentation- Chien-Ching Hung, MD, PhD

The emergence of transmitted protease inhibitor resistance mutations in adults starting antiretroviral therapy in northern Vietnam- Dr. T. Le

Highly automated deep sequencing-based HIV-1 drug resistance monitoring system- Dr. E. Rakhmanaliev

Drug interactions between anti-HCV Antivirals Ledipasvir/Sofosbuvir and integrase strand transfer inhibitor-based regimens- Dr. D. Mccoll

HIV and adolescents: How do we help them to prepare for adult lifeation?- Rangsima Lolekha

Transition into adult care: Factors associated with level of preparedness among adolescents living with HIV in Cambodia- Dr. S. Yi

Factors associated with HIV infection among transgender women in Cambodia: Results from a national integrated biological and behavioral survey- Dr. S. Yi

Renal disease and HIV- Sanjay Pujari

Cardiovascular disease and HIV- Somnuek Sungkanuparph

Assessment of atherosclerotic cardiovascular disease (ASCVD) risks between HIV-infected patients receiving first-line and second-line antiretroviral therapy- Dr. J. Tiarukkitsagul

Higher burden of chronic comorbidities among aged hospitalized HIV patients compared to non-HIV infected patients in Japan- Dr. D. Ruzicka

Prevalence of sarcopenia and associated risk factors among HIV-infected individuals receiving suppressive antiretroviral therapy- Dr. R. Rajasuriar

Recruiting people into HIV Services: eBooking- Panus Na Nakorn

Online platforms to spur HIV testing- Joseph Tucker, MD, PhD, AM

e-Cascade for real-time monitoring of HIV program- Matthew Avery

Consideration regarding the service model on pre-exposure prophylaxis for men who have sex with men in the community- Dr. T.H. Kwan

Pre-exposure prophylaxis uptake among men who have sex with men at a clinic in Bangkok, Thailand, 2016- Dr. W. Wimonsate

Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia- Dr. R. Sopha

Population-based PrEP implementation in New South Wales, Australia- Andrew Grulich

Round Table Discussion: True demand from the communities- Midnigh Poonkasetwattana

Round Table Discussion: Genuine supply from the providers- Rossana Ditangco

PrEP research and implementation gaps- Michael Cassell

Access to treatment/care on the global level- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

Access to treatment/care on the country level- Giten Khwairakpam

Barriers to access - Community perspective- Martin Choo, MMedSc

New HIV drugs / regimens- Daniel Kuritzkes, MD

New hepatitis drugs- Jürgen Rockstroh, MD

Innovative ways to stimulate the demand of HIV and HCV testing- Philip Cunningham

Effectively Communicating Your Research Objectives in Grant Applications - S. Lewin, AO, FRACP, PhD, FAHMS

Thank you - S. Lewin